7 April 2022
BerGenBio ASA: BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
Bergen, Norway – 7 April 2022: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 28 April 2022 at 10:00 hours (CEST).
The notice, power of attorney and proposal from Nomination Committee are attached to this release. The notice will be sent to all registered shareholders and is available on the Company’s website: https://www.bergenbio.com/investors/general-meetings/
All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the person he appoints), or to attend the general meeting virtually.
Advance vote or proxy for the Annual General Meeting can be registered through the company’s website or VPS Investor Service within 25 April 2022 16:00 hours (CEST). Virtual participants need to be logged in to the meeting before 10:00 hours (CEST) 25 April 2022.
All shareholders will receive a reference number and a pin code required for registration through the company’s website. Reference number and pin code will be received either by VPS Investor Service or by post depending if the shareholder is registered as electronical user.
We encourage all shareholders to register as electronical user in VPS.
– END –
AboutBerGenBioASA
BerGenBiois a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company’s proprietary lead candidate,bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broadphase II clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,tilvestamab, is undergoingphase I clinical testing. In parallel,BerGenBiois developingacompanion diagnostic test to identify patient populations most likely to benefit frombemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Contacts
Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
